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In lytically infected B cells Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 gene encodes two RNA
isoforms by alternative splicing of its pre-mRNA, which contains a small, constitutive intron in its 50 half
and a large, suboptimal intron in its 30s half. The RNA1 isoform encodes full-length ORF57 and is a major
isoform derived from splicing of the constitutive small intron, but retaining the suboptimal large intron
as the coding region. A small fraction (o5%) of ORF57 RNA undergoes double splicing to produce a
smaller non-coding RNA2 due to lack of a translational termination codon. Both RNAs are cleaved and
polyadenylated at the same cleavage site CS83636. The insertion of ORF57 RNA1 into a restriction cutting
site in certain mammalian expression vectors activates splicing of the subopitmal intron and produces a
truncated ORF57 protein.
Published by Elsevier Inc.Introduction
Kaposi sarcoma-associated herpesvirus (KSHV, human her-
pesvirus 8 or HHV8) open reading frame (ORF) 57 is a post-
transcriptional regulator of viral gene expression [for review see
(Majerciak and Zheng, 2015)] essential for virus gene expression
and replication (Majerciak et al., 2007; Han and Swaminathan,
2006; Verma et al., 2015). A full-length ORF57 protein, naturally
occurring as a homodimer (Majerciak et al., 2015), is composed of
455 amino acid (aa) residues. In KSHV-infected cells, ORF57 is
encoded by an abundant monocistronic transcript initiated from
an inducible promoter P82003 controlled by KSHV transactivator
RTA (ORF50) (Lukac et al., 1998). The nascent transcripts are ter-
minated at a polyadenylation cleavage site (CS) at nt 83636 in the
virus genome, downstream of ORF57 coding region (Fig. 1A)
(Majerciak et al., 2006; Majerciak et al., 2013; Arias et al., 2014).
The maturation of an ORF57 mRNA requires RNA splicing of a
small intron (intron 1) in size of 108 nts from nt 82117 (50 donor
splice site) to nt 82226 (30 acceptor splice site) at the 50 half of the
pre-mRNA (Bello et al., 1999; Majerciak et al., 2006).
A recent study by RNA-seq using epithelial iSLK cells harboring
recombinant KSHV.219 (iSLK-219) suggests the possible presence
of a novel, unrecognized 571-nt long intron (intron 2) in the 30 half
of ORF57 transcript (Arias et al., 2014) (Fig. 1A). The predicted
double spliced ORF57 RNAwas proposed to encode a novel, 299-aaheng).long ORF57A protein which consists of the N-terminal 266-aa
residues of ORF57 fused with 33-aa residues from a newly-created
off-frame exon 3. While being extrapolated based on the obser-
vation of ribosome occupancy at the exon 3, the existence of
ORF57A protein expression remained questionable. First, the
expression of ORF57A would require the double spliced ORF57
RNA to read through the polyadenylation CS83636 site to utilize a
translation termination (STOP) codon further downstream
(Fig. 1B). Second, the double spliced ORF57 RNA was detected at
low frequency only in the iSLK-219 cells infected by a recombinant
virus with the insertion of a GFP/RFP (green and red ﬂuorescent
proteins) reporter cassette downstream of ORF57 in its KSHV
genome (Vieira and O'Hearn, 2004), but not in the cells infected by
a native KSHV virus (Arias et al., 2014). Thus, this splicing was
suspected as a result of undesirable activation of cryptic ORF57
RNA splicing by the insertion of a reporter GFP/RFP downstream of
ORF57 gene.Results and discussion
ORF57 RNA undergoes alternative splicing during KSHV lytic infection
in PEL cells
To investigate the possible presence of authentic double spli-
cing of ORF57 during native KSHV infection, we performed RT-PCR
analysis of ORF57 transcripts extracted from three primary effu-
sion lymphoma (PEL) cell lines, including JSC-1, BCBL-1 and
engineered BCBL1-TREx-RTA (TREx) (Renne et al., 1996; Cannon et
V. Majerciak, Z.-M. Zheng / Virology 488 (2016) 81–8782al., 2000; Nakamura et al., 2003), with undergoing KSHV lytic life
cycle. To detect splicing of the putative intron 2, a forward primer
(oVM96) located upstream of the putative ORF57 intron 2 was
combined with a reverse primer (oNP18) immediately upstream of
the CS83636 site (for details see Fig. 1A and Table 1). As shown in
Fig. 1C, we detected two distinct RT-PCR products from all three
cell lines: a major product in size of 932 nts with intron2 retention representing RNA1 and a minor product in size of
361 nts representing the RNA2 with intron 2 exclusion (lanes 1–
6). No ampliﬁcation was detected in the absence of reverse tran-
scription (RT-), conﬁrming RNA origin of the detected amplicons.
The amount of the RNA2 derived from double splicing varied
among individual cells lines with JSC-1 cells showing the lowest
level. DNA sequencing of the gel-puriﬁed RNA2 product revealed
Table 1
Primers used in this study.
Name Position Sequence Assay
oVM12 82699-
82718
50-CTCAGACTCCCTGCGAGCAT-30 30RACE
oVM36 83438-
83454
50-TGGAACATCACAGCTTG-30 30RACE,
RPAa
oVM67 83254-
83274
50-GCATGTAACCTTCTTGGCGAG-30 30RACE
oVM90 83705-
83687
50-taatacgactcactatag/
GGCGGTCTGGTGTTGTGTT-30
RPAa
oVM96 82675-
82695
50-tactcagaattcaccatg/
GGTGTGTCTGACGCCGTAAAG-30
RT-PCR,
30RACE
oNP18 83606-
83583
50-atcgtgttaac/GAGAAAGGCTACGTGAGT-
TACATG-30
RT-PCR
oVM280 83667-
83647
50-GAGAAGAGACCACGCCTGACT-30 RT-PCRb
oZMZ296 N/A 50-gcatggcggacttgaagaa-30 (vector) RT-PCR
oVM79 N/A 50-gggcactggagtggcaac-30 (vector) RT-PCR
BGH N/A 50-tagaaggcacagtcgagg-30 (vector) RT-PCR
Primer positions are based on KSHV genome sequence GenBank Acc. No. U75698.1.
The lower case marks non-KSHV sequences.
a Primers used to prepare DNA template for RNA probe by in vitro transcription,
with oVM90 attached by a T7 promoter sequence;
b Primer identical to Rev-C from (Arias et al., 2014). BGH, bovine growth
hormone sequence from the vector.
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genome (Fig. 1D), consistent with the proposed intron 2 splice
sites identiﬁed in iSLK.219 cells (Arias et al., 2014). No other
alternatively spliced isoform of ORF57 RNA was detected using
others primer sets (data not shown). Thus, our data indicate the
presence of an authentic RNA2 as a result of double splicing of
ORF57 RNA in PEL cells with KSHV lytic infection.
To determine whether or not the RNA2 runs over the identiﬁed
CS83636 site to reach a translation termination codon, we per-
formed an RT-PCR using the same forward primer (oVM96) in
combination with a reverse primer (oVM280) immediately
downstream of the CS83636 site corresponding to the Rev-C primer
used in Arias's study (Arias et al., 2014). Using this set of primers
we also detected RNA1 from all three cell lines with lytic KSHV
infection, with TREx BCBL1-RTA cells being the most (Fig. 1C, lanes
7–12). However, the amounts of RNA1 products ampliﬁed from
this primer set (Fig. 1C, lanes 7–12) were substantially lower than
the amount ampliﬁed from the primer set (oVM96þoNP18) with a
reverse primer oNP18 immediately upstream of the CS83636 site
(see Fig. 1C, lanes 1–6). Using this primer set the RNA2 was not
detectable, but could be ampliﬁed with more cycles (data not
shown). In contrary to Arias et al., we were also able to detect
other longer RNA products by using a reverse primer (Rev-D)
further downstream from K9 coding region (data not shown).Fig. 1. KSHV ORF57 gene encodes two isoforms of alternatively spliced RNA. (A) Diagram
gray arrow), the transcriptional starting site (P) at nt 82003 and the polyadenylation c
RNA2) are shown below. The numbered boxes represent exons separated by introns (d
determined from the Northern blots shown in (F) determined by ImageJ analysis (http:/
thick line for an antisense RNA-probe used for Northern blot and RPA. The nucleotid
U75698.1). (B) Amino acid composition of the hypothetical ORF57A encoded by RNA2 der
ORF57 polyadenylation cleavage site (CS), respectively. The classical polyadenylation sign
of the CS83636 site are also indicated in this panel. (C) Alternative splicing of ORF57 exon 2
lines. The viral lytic cycle was induced by 48 h treatment with 1 mM valproic acid (BCBL-1
step RT-PCR was carried out on total RNA by reverse transcription (RTþ) with random h
primers. The size and concentration of obtained PCR products were determined by Bioan
(D) A chromatograph shows the exon–exon junction of ORF57 intron 2 splicing determin
transcripts at the CS83636. The nested 30RACE was carried out on total RNA from lytic T
oVM12 and oVM36 for the second (nested) ampliﬁcation. The resulting products wer
determined by Sanger DNA sequencing of each nested 30RACE product. (F and G) Express
from JSC-1 cells with latent (–) and lytic (Bu-butyrate treated) infection used for ORF57 N
antisense RNA-probe as described in the panel A (F). Total cell RNA from JSC-1 cells w
protection assay (RPA) by the same antisense RNA probe described in the panel A (G).Together, our data suggest that the majority of ORF57 RNA iso-
forms are cleaved at the CS83636 site for polyadenylation and only a
minimal fraction in BCBL-1 and JSC-1 cells could run through the
CS83636 site. Why the ORF57 RNA1 could run through the CS83636
site more often in TREx BCBL-1-RTA cells than its parent BCBL-1
cells remains to be further investigated.Both ORF57 RNA1 and RNA2 are polyadenylated from the CS83636 site
To examine whether another possible alternative poly-
adenylation site is used by a small fraction of the ORF57 RNA
isoforms running over the CS83636 site, we carried out nested
30RACE analysis on total RNA from TREx BCBL1-RTA cells (Naka-
mura et al., 2003) with high level of KSHV lytic induction. For this
purpose, two forward primers (oVM96/oVM12) located upstream
of the intron 2 50 splice site (Fig. 1A) were chosen for this study.
The primers (oVM67/oVM36, Fig. 1A) within the intron 2 pre-
viously used for ORF57 cleavage site mapping served as a positive
control (Majerciak et al., 2006) . In accordance with our previous
report, we found that the intron 2-speciﬁc primers ampliﬁed only
a single 30 RACE product corresponding to ORF57 RNA1 (Fig. 1E,
lane 1). However, the primer upstream the intron 2 led to amplify
two 30 RACE products with the size corresponding to the RNA1 and
RNA2, respectively (Fig. 1E, lane 2). DNA sequencing of all three
30RACE products (Fig. 1E, lanes 1 and 2) revealed that they are all
cleaved at a single cleavage site, CS83636 site (Majerciak et al., 2013;
Majerciak et al., 2006) . We did not identify any other alternative
polyadenylation site for ORF57 RNA polyadenylation. Thus, the
CS83636 site identiﬁed in our previous report (Majerciak et al.,
2013; Majerciak et al., 2006) is the only polyadenylation site for all
isoforms of ORF57 transcripts during KSHV lytic infection. We
conclude that the transcripts running over the CS83636 are rare and
if any, might be polyadenylated by using a non-canonical pA signal
or cleavage site and even so, might be accompanied by RNA-
degradation pathways (Wyers et al., 2005). Lack of deﬁned poly-
adenylation sites downstream of the reported CS83636 site was
further supported by the observation that the level of the ampli-
ﬁed ORF57 transcripts was gradually decreased along with
increased distance of the reverse primers from the CS83636 site
(data not shown). This is consistent with the proposed torpedo
model for termination of RNA polymerase II transcription (Logan
et al., 1987; Connelly and Manley, 1988). Finally, the usage of the
reported CS83636 site for polyadenylation of ORF57 RNA2 indicates
that intron 2 splicing does not affect the CS83636 selection as
observed in other mammalian transcripts (Tian et al., 2007).of the KSHV ORF57 locus in the virus genome showing the ORF57 coding region (big
leavage site (CS) at nt 83636. The alternatively spliced RNA transcripts (RNA1 and
ashed lines). On the right is the expression level of individual ORF57 transcripts
/imagej.nih.gov/ij/). Arrows below the RNA2 are primers used in this study, with a
es positions are based on the sequence of the KSHV genome (GenBank Acc. No.
ived from double splicing. Arrows mark the positions of the exon–exon junction and
al (PAS) AAUAAA of ORF57 and reverse primers (colored) upstream or downstream
during KSHV lytic infection in three KSHV-infected primary effusion lymphoma cell
), 3 mM sodium butyrate (JSC-1) or 1 mg/ml of doxycycline (TREx BCBL1-RTA). Two-
examers followed by 25 cycles of PCR ampliﬁcation with the indicated gene-speciﬁc
alyzer 2100 (Agilent). The reactions without RT (–) were used as a negative control.
ed by Sanger sequencing of spliced RT-PCR products. (E) Polyadenylation of ORF57
REx BCBL1-RTA cells. The primers oVM96 and oVM67 were used for the ﬁrst and
e analyzed by agarose gel electrophoresis. The polyadenylation cleavage site was
ion proﬁle of ORF57 transcripts in KSHV-infected cells. Total or poly A-selected RNA
orthern blot in our previous publication (Majerciak et al., 2006) was re-probed by an
ith or without butyrate treatment for lytic infection was also examined by RNase-
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transcripts
To determine the exact level of ORF57 intron 2 splicing during
lytic KSHV infection, we next examined the expression level of
ORF57 RNA2 in KSHV-infected cells. We re-analyzed previously
published mapping of ORF57 transcripts in JSC-1 cells (Majerciak
et al., 2006) using a 32P-labeled antisense RNA-probe (see Fig. 1A)
spanning over the intron 2 and exon 3 regions from the ORF57
RNA 30end by other two common methods. First, by Northern
blotting with adjusted exposure, we clearly detected two isoforms
of ORF57: a previously reported, abundant RNA1 of 1.5 kb in size
and the newly identiﬁed RNA2 with predicted size of 1 kb
(Fig. 1F). Both isoforms were present only in samples with lytic,
but not latent infection (Fig. 1F, compare lanes 2 and 4 to lanes
1 and 3) and were enriched in polyadenylated RNA fraction (lane
4). This is in accordance with ORF57 RNA being a lytic and poly-
adenylated transcript (Bello et al., 1999; Majerciak et al., 2006;
Majerciak and Zheng, 2009). Based on signal intensity of each
ORF57 mRNA isoform, we found that the RNA2 accounts for only
o5%, whereas the RNA1 accounts for 95% of the polyadenylated,
total ORF57 RNA. The low abundance of the RNA2 was also con-
ﬁrmed by RNase-protection assays using the same 30 end probe on
the same RNA from the activated JSC-1 cells with KSHV lytic
infection. As shown in Fig. 1G, we again detected only a trace
amount of the RNA2, with the majority of protected probe hybri-
dized to the RNA1 (lane 2). The presence of two protected frag-
ments for both RNA1 and RNA2 represents the heterogeneity in
selection of the polyadenylation cleavage site CS83636 due to its
suboptimal nature of a downstream GU-rich region (Majerciak et
al., 2006). Consistent with our 30RACE results in Fig. 1E, RPA did
not detect any notable ORF57 transcripts being polyadenylated at
another cleavage site further downstream.
Nevertheless, our data show that native KSHV infection does
produce a minor, double spliced ORF57 RNA2 that is poly-
adenylated at the CS83636. As a result, the RNA2 would be non-
coding due to lack of a functional translational stop codon and
thus would subject to non-stop RNA decay [for review see (Lykke-
Andersen and Bennett, 2014)]. Though a small, undetectable
fraction of the RNA2 might escape the CS83636 to use another non-
canonical cleavage site further downstream for its polyadenyla-
tion, the existence of a possible ORF57A protein translated from
such a rare RNA2 is negligible and its biological signiﬁcance would
require further experimental validation.
Homologous EB2 from Epstein-Barr virus shares the similar
gene structure with KSHV ORF57. EB2 protein is also expressed
from a monocistronic mRNA generated by splicing of a small
constitutive intron at the 50-half of nascent EB2 transcript (Batisse
et al., 2005). Despite that bioinformatics analysis of the EB2
sequence could predict a potential alternative intron at the EB2 30-
half, we were unable to detect, by RT-PCR, any double spliced EB2
RNA from activated JSC-1 cells co-infected with KSHV and EBV or
Raji cells infected with EBV only (data not shown).
Selective activation of ORF57 alternative splicing from mammalian
expression vectors
Given that the intron 2 30 splice site of ORF57 RNA is out of frame
by one nt after the ORF57 stop codon UAA, it is generally removed
by cloning the coding region of ORF57 RNA1 into a mammalian
expression vector (Fig. 2A). However, by RT-PCR we unexpectedly
detected the spliced ORF57 RNA species expressed from some of
several expression vectors in HEK293 cells using a pair of primers,
one upstream of the ORF57 intron 2 50 splice site and one down-
stream of the protein tag coding region (Figs. 2A and 2B). There was
no detectable RNA splicing from untagged ORF57 or ORF57 with aC-terminal FLAG tag (Fig. 2B, lanes 2 and 6). A high level of RNA
splicing was seen in the ORF57 fused with a C-terminal V5-His tag,
c-myc tag, or HA tag (Fig. 2B, lanes 4, 8, and 10). As a result, the
latter three vectors failed to efﬁciently express a full-length ORF57
protein, but instead express mostly a truncated form of ORF57
protein (Fig. 2C, lanes 3–5). Analysis of exon–exon junctions in the
spliced RNA from those vectors showed that the splicing took place
from the intron 2 50 splice site of ORF57 to a new 30 splice site
within the vector multiple clone site sequences (Fig. 3A). The vec-
tors expressing no detectable ORF57 splicing (untagged ORF57 and
ORF57-FLAG) lack a notable 30 splice site at this location (Fig. 2B,
lanes 2 and 6). However, in the case of ORF57-GFP vector where GFP
was fused to the ORF57 C-terminus (Fig. 2D) via a Bam HI site in a
pEGFP-N1 vector, this clone site in pEGFP-N1 does not bear a 30
splice site, but evident splicing of ORF57-GFP RNA was identiﬁed in
HEK293 cells (Fig. 2D). By sequencing of the spliced product, we
found this fusion transcript was spliced from the intron 2 50splice
site of ORF57 to a cryptic 30 splice site in the GFP coding region
(Fig. 2D and E and Fig. 3B). This splicing happens in-frame and leads
to express a chimeric, truncated ORF57-GFP protein which contains
the N-terminal 266-aa residues of ORF57 and the C-terminal 235-aa
residues of GFP. Thus, the chimeric, truncated ORF57 can be
recognized both by an anti-GFP antibody and an anti-ORF57
N-terminal antibody recognizing the epitope upstream of the
intron 2, but not by an antibody against the ORF57 C-terminal
epitope resided in the intron 2 (Fig. 2D and F).
Splicing efﬁciency of the ORF57 intron 2 is regulated by the strength
of 30 splice site
Most of eukaryotic introns are GU-AG introns, with GU dinu-
cleotide being a 50 (donor) splice site and AG dinucleotide being a
30 (acceptor) splice site. Immediately upstream of the 30 splice sites
are featured by a branch point sequence and a polypyrimidine
track which are recognized ﬁrst by cellular splicing machinery to
facilitate intron excision (splicing) from a nascent transcript
(Zheng, 2004). The ﬁrst intron in the 50 half of ORF57 RNA is a
constitutive intron, with a small (114 nts), capped exon immedi-
ately upstream and thereby, its splicing can be efﬁciently pro-
moted by the capping machinery cross over the exon (Konarska et
al., 1984; Lewis et al., 1996; Zheng et al., 2004). In addition to the
suboptimal feature of the intron 2, a large size (749 nts) of the
internal exon 2 upstream of the intron 2 may also prevent
recognition of the intron 2 50 splice site by the cellular splicing
machinery. It has been well documented that the size of an
internal exon affects cross-talk (exon deﬁnition) of a 30 splice site
and a 50 splice site over the exon and this cross-talk is limited by
an oversized exon (4500 nts) (Robberson et al., 1990; Sterner et
al., 1996; Zheng, 2004; Ajiro et al., 2012). Moreover, the intron 2 30
splice site AG in ORF57 is preceded by unfavorable A and may also
contribute to a low level of intron 2 splicing during native KSHV
infection (Fig. 3A) since a nucleotide preceding the AG has striking
inﬂuence on selection of a 30 splice site. The order of competi-
tiveness in the splicing scanning model has a nucleotide pre-
ference of CAG congruent to UAG4AAG4GAG at this position
(Smith et al., 1993). By insertion of ORF57 ORF into an XbaI site of a
pFLAG-myc-CMV-22 vector or a pcDNA3.0-HA vector, the strength
of 30 splice site is increased from AAG to UAG, leading to efﬁcient
splicing of ORF57 RNA (Fig. 3A). While insertion of genomic ORF57
region into a pcDNA3.1/V5-His TOPO vector remains the 30 splice
site AAG unchanged (Fig. 3A), but the majority of the RNA was
spliced even though a small fraction of the full-length ORF57
protein can be expressed (Fig. 2C). One interpretation is that a U
upstream of the AAG in the ORF57 intron 2 30 splice site was
missing from the inserted ORF57 intron 2 in the TOPO vector and
the nucleotide U is suppressive to RNA splicing (Tanaka et al.,
Fig. 2. Activation of an alternative RNA splicing during ORF57 ectopic expression. (A) Diagrams of various ORF57 expression vectors generated by cloning the ORF57 (gray)
coding region with (gORF57) or without intron 1 into various eukaryotic expression vectors (for details see Materials and methods ). The protein tags fused to ORF57 proteins
are shown in red. The small arrows below each diagram are the primers used in RT-PCR. PCMV, cytomegalovirus early promoter; pA, polyadenylation site. (B) Detection of
ORF57 transcripts expressed from various expression vectors shown in the panel (A). RT-PCR was performed on total RNA isolated from HEK293 cells 24 h after plasmid
transfection with the primer sets (Table 1) indicated below. The reactions without RT () were used as a negative control. The resulting products were analyzed by
Bioanalyzer 2100. (C) Expression of truncated (trnc) ORF57 protein from spliced ORF57 RNA. Western blot analysis of ORF57 protein expression from the indicated vector in
HEK293 cells was performed 24 h after transfection. The protein samples were analyzed by SDS-PAGE and blotted by an anti-ORF57 N-terminal antibody. (D) Diagrams of the
chimeric ORF57-GFP fusion expression, RNA splicing, and the resulted protein isoforms. ORF57 cDNA was inserted into pEGFP-N1 at BamHI site to express an ORF57-GFP
fusion. Unspliced and spliced chimeric RNAs were detected by RT-PCR with the indicated primer set (small arrows). Dashed lines are the activated cryptic intron in size of
597 nts in this expression vector. On the panel right are the fused proteins expressed from individual transcripts, with its length in amino acid residues shown below. Shown
above the protein diagrams are the relative epitope positions for anti-ORF57 (N- or C-terminal) or anti-GFP antibody recognition. (E,F) Alternative splicing of chimeric ORF57-
GFP RNA and protein expression in HEK293 cells. The cells transfected with a GFP or chimeric ORF57-GFP expression vector were harvested 24 h after transfection for
analysis of total cell RNA (E) and proteins (F). Splicing of the chimeric ORF57-GFP RNA was detected from total cell RNA by RT-PCR using a primer pair of oVM96 and
oZMZ296 and the exon–exon junction was determined by DNA sequencing (E). Western blot of total cellular extracts was performed by an anti-GFP, anti-ORF57 N-terminal,
or anti-ORF57 C-terminal antibody (F). *, unknown proteins.
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sequence(s) from the TOPO vector is presumably also involved in
the enhanced splicing. In the case of the pFLAG-CMV-5.1 or pEGFP-
N1 vector, insertion of ORF57 ORF into its BamHI site disrupts the
intron 2 30splice site. Although a full-length ORF57-FLAG is
expressed from the pFLAG-CMV-5.1 vector, insertion of ORF57 ORFinto a pEGFP-N1 vector activates a cryptic 30 splice site in the 50
half of GFP ORF region downstream (Fig. 3B) and thereby leads to
partial production of truncated ORF57-GFP fusion protein. Alto-
gether, our data indicate that the accidental creation of a potential
splice site should be avoided in designing ORF57 expression in a
mammalian expression system.
Fig. 3. Sequence structure of the ORF57 intron 2 and its adjacent exons. (A) Diagram of an eukaryotic GU-AG intron and its important features (50 splice site [50 ss], branch
point sequence, polypyrimidine track, and 30 splice site [30 ss]). Below the diagram are the ORF57 suboptimal intron 2 and its native 30 splice site or an artiﬁcially created 30
splice site derived from the cloning site of individual expression vectors. Stop indicates a stop codon UAA in the native ORF57 ORF. In addition to the 50 splice site GU, the 30
splice site AG, and the branch point A in red color, a nucleotide preceding the AG dinucleotide in a 30 splice site is also colored in red to show its importance in selection of a
30 splice site. (B) Partial sequence view of the chimeric ORF57-GFP fusion region, with exon sequences in uppercase, intron sequences in lowercase, ORF57 in italic, and vector
in bold letters. The GFP sequences are underlined. The 50 splice site GU and 30 splice site AG and its preceding A are red colored. A BamHI site used for insertion of ORF57 ORF
into the pEGFP-N1 vector is shown.
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Cell lines, transfection and virus induction
KSHV-transformed primary effusion lymphoma (PEL) cell lines
JSC-1 (Cannon et al., 2000), BCBL-1 (Renne et al., 1996), and
BCBL1-TREx-RTA (Nakamura et al., 2003) were cultivated in
RPMI1640 medium supplemented with 10% fetal bovine serum
(FBS, GE Healthcare) and 1 Penicillin–Streptomycin–Glutamine
(PSG, Thermo Scientiﬁc). KSHV lytic replication was induced by
treatment of JSC-1 cells with 3 mM sodium butyrate, BCBL-1 cells
with 1 mM sodium valproate, or BCBL1-TREx-RTA cells with 1 mg/
ml of doxycycline, for period 24–48 h. HEK293 cells were grown in
complete DMEM medium with 10% FBS and 1 PSG. All trans-
fections were performed by LipoD293™ DNA In Vitro Transfection
Reagent (SignaGen Laboratories) as recommended.
Plasmids
All ORF57 expression vectors were generated by cloning of ORF57
genomic or cDNA fragments into various eukaryotic expression vec-
tors. The vector pVM1 expressing C-terminal V5-His-tagged ORF57
was generated by TOPO cloning of genomic region of ORF57 into
pcDNA3.1D/V5-His-TOPO vector (Invitrogen). The pcDNA3.0 (Invitro-
gen) containing ORF57 cDNAwas used for the expression of untagged
ORF57, pFLAG-CMV-5.1 (Sigma) for the expression of C-terminal
FLAG-tagged ORF57 (pVM7), pFLAG-myc-CMV-22 for the expression
of both N-terminal FLAG- and C-terminal myc-tagged ORF57
(pVM78), pcDNA3-HA for the expression of C-terminal HA-taggedORF57 (pVM79), and pEGFP-N1 (Clontech) for the expression of
ORF57-GFP fusion protein.
Two-step RT-PCR
Total RNA prepared by TRIpure reagent (Roche) was ﬁrst trea-
ted with TURBO DNA-free Kit (Ambion) to remove residual con-
taminant DNA before RT-PCR. RT was carried out on 1 mg of total
RNA using random hexamers with MuLV Reverse Transcriptase
(Applied Biosystems) at 42 °C for 1 h followed by PCR with a pair
of gene-speciﬁc primers using GeneAmp RNA PCR Ampliﬁcation
kit (Applied Biosystems). The sequences and position of primers
used in the study are summarized in Table 1.
Northern blot
Poly A-selected RNA was prepared form total RNA using illustra
QuickPrep mRNA Puriﬁcation Kit (GE Healthcare). Total and polyA-
selected RNA were separated on formaldehyde containing 1.2%
agarose gel and transfer to a nylon membrane. KSHV ORF57
transcripts were detected by a 32P-labeled RNA antisense probe
prepared by in vitro transcription on PCR DNA template using
Riboprobe System-T7 (Promega).
RNase-protection assay (RPA)
RNase-protection assay was carried out using RPAIII kit
(Ambion). Total RNA was co-precipitated with a 32P-labeled RNA
antisense probe. The pelleted RNA was dissolved in 10 ml on
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unprotected RNA probe by hybridization was removed by RNase A/
T1 digestion for 1 h at 37 °C. The protected RNA probe during
hybridization was separated on a denaturing 8% urea PAGE gel,
with 32P-labeled 100 bp DNA Ladders being size markers.
30RACE
RNA polyadenylation sites were determined using SMARTer
RACE 50/30 Kit (Clontech) using 1 mg of total RNA as recommended
by manufacturer. The RACE products from the ﬁrst ampliﬁcation
were diluted 1:50 and used as template for the second ampliﬁca-
tion with nested primers. The resulted RACE products were sepa-
rated on an agarose gel and puriﬁed for direct Sanger sequencing.
Western blotting
Total protein extract was prepared by direct cell lysis in
Laemmli SDS protein sample buffer supplemented with 5% (vol/
vol) of 2-Mercaptoethanol and was separated on a gradient SDS-
PAGE gel. After transfer to a nitrocellulose membrane, ORF57 and
its fusions were blotted with an anti-ORF57 N- or C-terminal
antibody (Majerciak et al., 2010; Majerciak et al., 2015) or an anti-
GFP (Clontech) antibody.Acknowledgment
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